SB 9200 RSV and Other Development Programs

Subject to obtaining additional financing beyond the proceeds from our IPO, we plan to explore the development of SB 9200 for the treatment of RSV, HIV latency and HDV. If we determine to proceed with development of SB 9200 for RSV, we would expect to initiate a Phase 2 clinical trial of SB 9200 in otherwise healthy adult volunteers inoculated with RSV. If we determine to proceed with clinical development of SB 9200 for HIV latency, we would seek to collaborate with major research centers and third parties with significant expertise in HIV to explore the potential use of SB 9200 in the eradication of HIV. In addition, we believe that therapies such as SB 9200, which can reduce or cause loss of HBsAg, may play an important role in the treatment of HDV co-infected HBV patients.


RSV infection leads to 2.1 million outpatient visits and 57,000 hospitalizations among children younger than five years old.

Learn more about RSV